← Back

Wire · opportunities

FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The FDA granted accelerated approval to neladalkib for previously treated ALK-positive locally advanced or metastatic non-small cell lung cancer, supported by phase 1/2 ALKOVE-1 trial data showing meaningful overall response rates and durable responses in heavily pretreated patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You have a new option to pitch for ALK-positive lung cancer after multiple prior therapies. This approval opens a door to users who failed existing ALK drugs, so tailor your clinical or commercial approach accordingly.

◆ Coverage

3 sources · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalalk-positive-nsclcclinical-trialaccelerated-approvaltargeted-therapy